Jobs
View more job listings or post a job
InnoAlliance Scientist/Sr Scientist of Bioanalysis & Biomarkers
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Post a job

Workshop

[Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond


Speakers: Lixia Yao, Polygon Health Analytics LLC; Aaron Mackey, Lokavant; Ying Li, Regeneron Pharmaceuticals, Inc.; Daisuke Goto, Organon & Co.; Star Chen, Merck & Co.
Organizers: Lixia Yao - Founder & CEO, Polygon Health Analytics LLC
Date: 2024-10-25
Time: 8:30-12:00 Pacific Time
Registration fee: Free
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2024-10-24  (it will close sooner if the seating cap is reached)

About the Topic

Real-world data (RWD) are data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources, and Real-world evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of RWD. In this workshop, we delve into the transformative power of RWD and RWE in the pharmaceutical industry, which may transform every facet of the pharma industry from discovery to marketing. 

The following topics will be covered:

  • Definitions, sources, and implications of RWD and RWE in today’s healthcare landscape. 
  • RWD and RWE for drug discovery, highlighting how RWD can identify new therapeutic targets and accelerate new drug discovery
  • The role of RWD in clinical development, including designing innovative trials, enhancing patient recruitment, and improving outcomes
  • Health Economics and Outcome Research (HEOR), demonstrating the potential of RWD/RWE in cost-effectiveness analysis, budget impact analysis, and health technology assessment
  • Strategic utilization of RWD in pharma marketing, discussing how it can inform strategies, support product positioning, and provide insights into market dynamics
  • FDA's approaches on RWD and RWE for drug approval and regulation


2024-08-14, [Free Online] Advances in Cancer Therapeutics (Organized by PBSS and BioScience Forum)
2024-08-22, [Free Online] Diabetes and Obesity Treatments: Current and Emerging Landscapes of GLP-1, GIP, and Beyond
2024-09-10, [In-Person] Translational PK/PD and Human Dose Projection for Antibodies/ADCs and Novel Therapeutic Modalities
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
2024-09-25, [Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
2024-11-01, [In-Person] Clinical Pharmacology Studies on Hepatic and Renal Impairments for NDA Filing: Strategies, Design, Conduct, Analysis and Regulatory Aspects
2024-11-13, [Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
2024-11-15, [In-Person] Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapeutics
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
©Pharmaceutical & BioScience Society, International; Last Modified: 7/24/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Simulations Plus GastroPlus X: Science, models & refined algorithms—now with intuitive interface, faster processing & streamlined workflows for faster PBPK modeling.
Submit a Text Ad